Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2025 Earnings Call Transcript March 18, 2026 Sera Prognostics, Inc. beats earnings expectations. Reported EPS is $-0.15768, expectations were $-0.18897.

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...

When Sophia Babakhani graduated from high school, she knew she wanted to go to college — she just needed the right place to ...

With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, Inc.'s CMO ...

RESEDA, CA - March 19, 2026 - PRESSADVANTAGE - Moment of Clarity has published a comprehensive new educational resource ...

The foam manufacturer provides a clear framework to customers on how it approves and works with global fabricators and ...

As employers increasingly look to specialized Centers of Excellence to address complex neurological conditions and improve workforce recovery outcomes, CNS is expanding its engagement with the ...

Under an MOU with Lockheed Martin, Coexpair will use a phased approach to drive innovation for the F-35 program in Belgium ...

If you have not had a chance to review our quarterly earnings release, it can be found on our website at seraprognostics.com.

An Informational Consumer Analysis of AgelessRx's Prescription Process, NAD+ Therapies, GLP-1 and Compounded Semaglutide Options, Off-Label Longevity Medications, and Cash-Pay Pricing Structure for 20 ...

Welcome to Sera Prognostics fourth quarter and full fiscal year 2025 earnings conference call. At the close of mar ...

Ines Hwang ’28 interviews students studying fashion design and fashion design management to learn more about Cornell's fashion program.